Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described imidazo[4,5-b]pyridine and pyrazolo[1,5-a]pyrimidine derivatives acting as serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of juvenile idiopathic arthritis, nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.
Chiesi Farmaceutici SpA has divulged TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Mainline Biosciences (Shanghai) Co. Ltd. has described peptides acting as tachykinin NK1 receptor antagonists reported to be useful for the treatment of pain and opioid dependence.
Chulalongkorn University has divulged programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) modulators reported to be useful for the treatment of cancer.
Cincinnati Children’s Hospital Medical Center has identified IL-1 receptor-associated kinase (IRAK) and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has synthesized molecular glue compounds targeting protein cereblon (CRBN) acting as CRBN/target protein interaction inducers reported to be useful for the treatment of cancer.
Researchers at University of Arizona and University of Dundee have disclosed dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes, osteoarthritis, Down syndrome, inflammatory disorder, autoimmune and Alzheimer’s disease.
RSS